By:
On:
In: Commentary
With: 0 Comments

While you are enjoying the beginning of summer with a 3-day weekend. Please do not forget why you are not working today.

Remember those who served. All gave some and some gave all they had.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name Atlas Pipeline Partners, L.P.
Stock ticker APL
Live stock price [stckqut]APL[/stckqut]
P/E compared to competitors Fair

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $55.06
Target stock price (averages with growth) $51.35
Target stock price (averages with no growth) $25.89
Target stock price (manual assumptions) $47.35

The following company description is from Google Finance: http://www.google.com/finance?q=apl

Atlas Pipeline Partners, L.P. is a provider of natural gas gathering and processing services in the Anadarko and Permian Basins located in the southwestern and mid-continent regions of the United States; a provider of natural gas gathering services in the Appalachian Basin in the northeastern region of the United States and a provider of natural gas liquid (NGL) transportation services in the southwestern region of the United States. Its general partner, Atlas Pipeline Partners GP, LLC (Atlas Pipeline GP), manages its operations and activities through its ownership of its general partner interest. Atlas Pipeline GP is a wholly owned subsidiary of Atlas Energy, L.P, as well as the 2% general partner interest. The Company conducts its business in the midstream segment of the natural gas industry through two segments: Gathering and Processing and Pipeline Transportation. On December 1, 2012, the Company acquired Cardinal Midstream, LLC.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.
 

By:
On:
In: Fair company, Stock analysis
Tagged:
With: 0 Comments

Company name Viad Corp
Stock ticker VVI
Live stock price [stckqut]VVI[/stckqut]
P/E compared to competitors Fair

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Poor
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $40.91
Target stock price (averages with growth) $66.18
Target stock price (averages with no growth) $74.14
Target stock price (manual assumptions) $35.94

The following company description is from Google Finance: http://www.google.com/finance?q=vvi

Viad Corp (Viad) provides services primarily within the exhibition and events industry and travel and recreation industry. Viad serves clients primarily in North America, the United Kingdom, Germany and the United Arab Emirates. The Company’s organizes its businesses into two main operating groups: Marketing & Events Group and Travel & Recreation Group. The Marketing & Events Group specializes in all aspects of the design, planning and production of face-to-face events, immersive environments and brand-based experiences for clients, including show organizers, corporate brand marketers and retail shopping centers. The Travel & Recreation Group generates its revenues from tourism products and services, including hotel and concession operations, transportation services and package tour operations in and around Western Canada, Glacier National Park in Montana and Waterton Lakes National Park in Alberta, Canada. On March 7, 2012, Viad acquired Banff International Hotel and related assets.

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in this stock as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

By:
On:
In: Fair company, Stock analysis
Tagged:
With: 0 Comments

Company name Myriad Genetics, Inc.
Stock ticker MYGN
Live stock price [stckqut]MYGN[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Good
EPS growth Good
P/E growth Poor
EBIT growth Good

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $27.41
Target stock price (averages with growth) $31.67
Target stock price (averages with no growth) $23.44
Target stock price (manual assumptions) $27.16

The following company description is from Google Finance: http://www.google.com/finance?q=mygn

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual’s risk for developing disease later in life (predictive medicine), identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment (personalized medicine), or assess a patient’s risk of disease progression and disease recurrence (prognostic medicine).

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in this stock as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name Merck & Co., Inc.
Stock ticker MRK
Live stock price [stckqut]MRK[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Fair
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $67.23
Target stock price (averages with growth) $80.66
Target stock price (averages with no growth) $70.94
Target stock price (manual assumptions) $64.58

The following company description is from Google Finance: http://www.google.com/finance?q=mrk
Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company’s operations are principally managed on a products basis and consists of four segments: the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment: the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. In May 2011, it acquired Inspire Pharmaceuticals, Inc. In September 2011, the Company sold its 50% interest in the Johnson & Johnson-Merck Consumer Pharmaceuticals Company joint venture. In December 2011, the Company established an Asia Research & Development (R&D) headquarters for drug discovery and development located in Beijing, China.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.